Symbiotec Pharmalab IPO oversubscribed 71 times
Analysis based on 21 articles · First reported Aug 19, 2026 · Last updated Aug 27, 2026
The IPO's strong subscription indicates robust investor appetite for pharmaceutical and biotechnology companies in India, potentially boosting sentiment for the sector. The listing is expected to generate significant returns for investors, given the grey market premium of Rs 345, and may attract further capital to the API manufacturing segment.
Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, launched its initial public offering (IPO) on August 24, 2026, with a price band of Rs 938-988 per share. The issue, which closed on August 27, 2026, comprised a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore by selling shareholders Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund III. The IPO was subscribed 71.26 times, driven by strong demand from non-institutional investors (12.18x) and retail investors. The company raised Rs 526.19 crore from anchor investors ahead of the issue. Proceeds from the fresh issue will be used for debt repayment and general corporate purposes. The company is a global leader in corticosteroid and steroidal-hormone APIs, with a backward-integrated manufacturing model. The shares are expected to list on the BSE and NSE on September 1, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard